BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30650942)

  • 1. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.
    Fuentes-Fayos AC; García-Martínez A; Herrera-Martínez AD; Jiménez-Vacas JM; Vázquez-Borrego MC; Castaño JP; Picó A; Gahete MD; Luque RM
    Minerva Endocrinol; 2019 Jun; 44(2):109-128. PubMed ID: 30650942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
    Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of microRNAs in GH-secreting pituitary adenomas.
    Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
    Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives.
    Guaraldi F; Ambrosi F; Ricci C; Di Sciascio L; Asioli S
    Best Pract Res Clin Endocrinol Metab; 2024 May; 38(3):101894. PubMed ID: 38614953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients' plasma.
    Niedra H; Peculis R; Litvina HD; Megnis K; Mandrika I; Balcere I; Romanovs M; Steina L; Stukens J; Breiksa A; Nazarovs J; Sokolovska J; Liutkeviciene R; Vilkevicute A; Konrade I; Rovite V
    Front Oncol; 2022; 12():894317. PubMed ID: 36158656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of aggressive growth hormone secreting pituitary adenomas.
    Donoho DA; Bose N; Zada G; Carmichael JD
    Pituitary; 2017 Feb; 20(1):169-178. PubMed ID: 27987061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
    Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
    J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
    Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
    Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
    J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
    Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
    Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
    Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
    Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.
    Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.